Rein Therapeutics 
Welcome,         Profile    Billing    Logout  
 4 Products   2 Diseases  4 Products   2 Trials   194 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALRN-6924 / Advancium Health Network
NCT05622058: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Terminated
1b
6
Europe, US, RoW
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Aileron Therapeutics, Inc.
Prevention of Chemotherapy-induced Myelosuppression
02/23
02/23
NCT03654716: Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Completed
1
21
US
ALRN-6924, Cytarabine, Cytosar
Dana-Farber Cancer Institute, TeamConnor Childhood Cancer Foundation, Cookies for Kids' Cancer, Aileron Therapeutics, Inc.
Leukemia, Brain Tumor, Solid Tumor, Lymphoma
07/23
07/23
NCT03725436: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Active, not recruiting
1
35
US
MDM2/MDMX Inhibitor ALRN-6924, ALRN-6924, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
07/25
07/25
LTI-03 / Rein Therapeutics
NCT06968845: A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Active, not recruiting
2
120
US
LTI-03, Dry Powder Inhaler, Placebo
Rein Therapeutics
Idiopathic Pulmonary Fibrosis (IPF)
05/27
05/27
NCT05954988: A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

Hourglass Jul 2024 - Sep 2024 : Topline results from P1b trial in IPF
Completed
1
24
Europe, US
LTI-03, Micronized dry powder in hard 2 piece hypromellose capsules, Placebo, Micronized lactose powder in capsule
Rein Therapeutics
Idiopathic Pulmonary Fibrosis
09/24
09/24
LT-05 / Rein Therapeutics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALRN-6924 / Advancium Health Network
NCT05622058: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Terminated
1b
6
Europe, US, RoW
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Aileron Therapeutics, Inc.
Prevention of Chemotherapy-induced Myelosuppression
02/23
02/23
NCT03654716: Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Completed
1
21
US
ALRN-6924, Cytarabine, Cytosar
Dana-Farber Cancer Institute, TeamConnor Childhood Cancer Foundation, Cookies for Kids' Cancer, Aileron Therapeutics, Inc.
Leukemia, Brain Tumor, Solid Tumor, Lymphoma
07/23
07/23
NCT03725436: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Active, not recruiting
1
35
US
MDM2/MDMX Inhibitor ALRN-6924, ALRN-6924, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
07/25
07/25
LTI-03 / Rein Therapeutics
NCT06968845: A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Active, not recruiting
2
120
US
LTI-03, Dry Powder Inhaler, Placebo
Rein Therapeutics
Idiopathic Pulmonary Fibrosis (IPF)
05/27
05/27
NCT05954988: A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

Hourglass Jul 2024 - Sep 2024 : Topline results from P1b trial in IPF
Completed
1
24
Europe, US
LTI-03, Micronized dry powder in hard 2 piece hypromellose capsules, Placebo, Micronized lactose powder in capsule
Rein Therapeutics
Idiopathic Pulmonary Fibrosis
09/24
09/24
LT-05 / Rein Therapeutics
No trials found

Download Options